FNCH — Finch Therapeutics Balance Sheet
0.000.00%
- $21.68m
- $5.64m
- $0.11m
- 28
- 23
- 89
- 44
Annual balance sheet for Finch Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 42.2 | 99.7 | 133 | 71 | 25.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.75 | 1.09 | 0.494 | 0.144 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 48.6 | 106 | 143 | 74.6 | 25.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.78 | 7 | 24.7 | 48.7 | 27.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 104 | 165 | 225 | 163 | 55.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.33 | 11.5 | 14.8 | 14.7 | 4.08 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 20 | 28 | 23.1 | 67.2 | 32.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 83.6 | 137 | 202 | 95.7 | 22.9 |
Total Liabilities & Shareholders' Equity | 104 | 165 | 225 | 163 | 55.4 |
Total Common Shares Outstanding |